Abstract: This article investigates a new heat extraction approach for application to high-specific-output electrical machines. The proposed technique employs thermally conductive heat guides (HGs) to ...

Ask the publishers to restore access to 500,000+ books. An icon used to represent a menu that can be toggled by interacting with this icon. A line drawing of the Internet Archive headquarters building ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

BOSTON - Praxis Precision Medicines, Inc. (NASDAQ:PRAX) announced Tuesday it will immediately convert its EMBRAVE3 registrational study for elsunersen in SCN2A developmental and epileptic ...

You’d be surprised how many young people can’t read this. One of its conclusions tells the sad tale. “Between 2020 and 2025, the number of students whose math skills fall below high school level has ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is among the hidden multibagger stocks to invest in. It reported positive results from the registrational cohort of the EMBOLD study on December 4. This ...

Praxis Precision Medicines, Inc. (PRAX) stock is soaring in trading today, up 35% at time of writing, with shares reaching a value of $260, their highest value since the beginning of 2022. Current ...

Having already claimed a win for the phase 2 study of its seizure drug, Praxis Precision Medicines is hoping fresh efficacy data will form the backbone of an approval application for the sodium ...

Praxis Precision Medicines has also announced a “successful” pre-NDA meeting with the FDA for its essential tremor drug candidate ulixacaltamide, for which an approval application is slated for early ...

Today, a brief rundown of news from Praxis Precision Medicines and Bristol Myers Squibb, as well as updates from Denali Therapeutics, Crescent Biopharma and AstraZeneca that you may have missed.